Watertown Bio Summer Break Quick Hits

Catching up on the latest news as things slow down for the summer.

Another Watertown Biotech Goes Public via Reverse Merger, and a Flurry of Leasing at the Arsenal

Plus Biolabs expansion and Labshare's new tenants

Neumora's Phase 3 Trial Miss and a Trio of VC Raises

Watertown companies have now raised $245 million in VC funds in 2026

Another Watertown Biotech Goes Public and the Commonwealth Claws Back Hiring Tax Credits

Plus pre-clinical data results and more!

Watertown's First Potential IPO since 2023, Remix's Positive Clinical Trial Results, and Triveni Jumps into the Eczema Market

Plus the Boston Business Journal covers the rise of Watertown's Biotech scene, and more

Kestrel's $1.45 billion AbbVie Deal, FDA Approves First Ever PROTAC, and Werewolf Breaks Arsenal Lease.

Plus more details on Windgap's big pharma partnership and a number of people moves.

ALS TDI moves to Arsenal Yards, Windgap Medical’s Big Pharma Collab, and Watertown’s Q1 fundraising numbers

Plus Addgene’s rebrand and Earth Day clean ups

C4's Partnership with Roche, Gilead Options Kymera degrader, and Astellas Licenses Dyno Capsid.

Plus the initial dosing of Enanta and Avencell's Clinical Trials

Watertown Bio Journal Club - Improving Vaccine Immunogenicity with Corner Therapeutics

the very model of a modern adjuvant general

Triveni's New Digs, 99 Coolidge's Tenant Bonanza, and Remix's FDA Fast Track Designation

Plus Addgenes' new partnership, and Neumora and Acrivon's cash flow updates

Parallel Bio's Expansion into Therapeutics, and We're Looking Out for More Potential Cash Flow Challenges -Watertown Bio News RoundUp

Plus, where key opinion leaders see Watertown's biotech sector heading.

Watertown Journal Club - Exploring the oRNA behind ORNA Therapeutics

Watertown's Emerging Rare Blood Disorder Therapy Cluster, Warning Signs For Werewolf, and Fallout for Disc Medicines-Watertown Bio News RoundUp

Join us next week in Charting Watertown’s Life Science Future

An FDA Rejection, A Big Pharma Purchase, and Charting Watertown's Life Science Future -Watertown Bio News RoundUp

Plus another $10 million in VC raised, Souffle inks a partnership with Bayer, and more

Watertown Bio Journal Club: Using Wearables to Measure ALS Progression

Plus science photography and more plastic-eating bacteria engineering.

Watertown Bio News RoundUp: 2025 Life Science Industry Report

Watertown is a bright spot during a turbulent time for the industry.

All About Watertown's VC Funding

2025 Funding numbers are in, 2026 early raises, Lyra Therapeutics runs out of time and more

Watertown Bio Journal Club: How Targeted is Targeted Protein Degradation?

Evaluating the potential impact of off-target degradation of KT-474

What we're looking forward to in 2026-Watertown Bio News RoundUp

Neumora's positive clinical data , new tenants at the Arsenal, and more

Kymera and Psithera's Funding Haul - Watertown Bio News RoundUp

A Multi-Million dollar public offering, the developing race for a dupilumab alternative, business awards, and more.

Watertown Bio Journal Club: Engineering Plastic Eating- and Concrete Laying Bacteria

Plus, How to design a PROTAC

Watertown Bio News Roundup: Cultivarium's Next Steps

Stratus Therapeutics winding down, Consider the ALS TDI for Giving Tuesday, and more

Labshares Expanding to Watertown

Neumora's Wegovy alternative, Dyno announces manufacturing pact, and more

Watertown Bio Journal Club - How Many Ways Can You Break a Protein?

Talking about proteases, PROTACs, and molecular glues. Plus new methods for mass spec tagging, viral inhibitors, and more.